TrialMechanisms of ageing and development2021

Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients.

Jacopo Sabbatinelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.